Meda responds to article in The Wall Street Journal
The Wall Street Journal has published an article that states that Valeant Pharmaceuticals International Inc. has made a takeover approach for Meda.
Meda’s board of directors has not received an approach of the kind that is described in the article. However, there are several collaborations between Meda and Valeant including Joint Ventures in Canada, Mexico and Australia.
For further inquiries, please contact:
Anders Larnholt, Vice President Corporate Development &
IR
ph: +46 709-458 878
MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.
Forward-looking Statements
This press release is not an offer to sell or a solicitation to buy
shares in Meda. This press release also contains certain
forward-looking statements with respect to certain future events
and Meda’s potential financial performance. These
forward-looking statements can be identified by the fact that they
do not relate only to historical or current facts, and may
sometimes include words such as “may”,
“will”, “seek”, “anticipate”,
“expect”, “estimate”, “intend”,
“plan”, “forecast”, “believe”
or other words of similar meaning. These forward looking statements
reflect the current expectations on future events of the management
at the time such statements are made, but are made subject to a
number of risks and uncertainties. In the event such risks or
uncertainties materialize, Meda’s results could be materially
affected. The risks and uncertainties include, but are not limited
to, risks associated with the inherent uncertainty of
pharmaceutical research and product development, manufacturing and
commercialization, the impact of competitive products, patents,
legal challenges, government regulation and approval, Meda’s
ability to secure new products for commercialization and/or
development and other risks and uncertainties detailed from time to
time in Meda AB’s interim or annual reports, prospectuses or
press releases. Listeners and readers are cautioned that no
forward-looking statement is a guarantee of future performance and
that actual result could differ materially from those contained in
the forward-looking statements. Meda does not intend, nor
undertakes, to update any such forward looking statements.
Posted: July 2011
